Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.

Parent Announcements (For Unsolicited or Investigator-Initiated Applications)

Parent announcements are broad funding opportunities that applicants can use to submit investigator-initiated applications for a range of popular programs. These announcements do not specify any particular area of scientific interest. They simply provide the standard forms and instructions needed to apply. Parent announcements are open for up to three years and are typically reissued to ensure continuity. They use standard due dates with three application, review, and award cycles each year.

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
HEAL Initiative: Understanding Individual Differences in Human Pain Conditions RFA-NS-25-020 (R01 - Clinical Trial Optional) R01 Clinical Trial Optional 02/07/2025 Rachel Altshuler, Ph.D.
Notice of Special Interest: Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed) NOT-OD-22-202 Clinical Trial Not Allowed 04/16/2025 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research PAR-22-099 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 05/08/2025 Richard Mazurchuk, Ph.D.
HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices RFA-NS-23-028 (RM1 Clinical Trial Optional) RM1 Clinical Trial Optional 06/10/2025 Rachel Altshuler, Ph.D.
Discovery and Development of Natural Products for Cancer Interception and Prevention RFA-CA-25-013 (UG3/UH3 Clinical Trial Not Allowed) UH3, UG3 Clinical Trial Not Allowed 06/14/2025 Altaf Mohammed, Ph.D.
HEAL Initiative: Translational Development of Diagnostic and Therapeutic Devices RFA-EB-22-002 (R18 Clinical Trial Not Allowed) R18 Clinical Trial Not Allowed 06/18/2025 Rachel Altshuler, Ph.D.
HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery NOT-NS-22-095 06/25/2025 Rachel Altshuler, Ph.D.
Notice of Special Interest (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials NOT-CA-23-071 07/01/2025 Ellen Richmond, M.S., GNP-BC
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers NOT-CA-23-004 07/02/2025 Matthew Young, Ph.D.
NCI Clinical and Translational Exploratory/Developmental Studies PAR-25-139 (R21 Clinical Trial Optional) R21 Clinical Trial Optional 07/02/2025 Marjorie Perloff, M.D.